Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma

Annals of Oncology

Volumn 19, Issue 10, 2008, Pages 1759-1764

  Mendle, J H ^a   Kelly, J ^a   Voci, S ^a   Marquis, D ^a   Rich, L ^a   Rossi, R M ^a   Bernstein, S H ^a   Jordan, C T ^a   Liesveld, J ^a   Fisher, R I ^a   Friedberg, J W ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Bortezomib; Gemcitabine; Hepatotoxicity; Hodgkin's lymphoma; Proteasome; Relapsed

Indexed keywords

BORTEZOMIB; GEMCITABINE; PROTEASOME;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER RELAPSE; CLINICAL TRIAL; CYTOPENIA; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG WITHDRAWAL; ENZYME INHIBITION; FEMALE; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; LEG ULCER; LEUKOPENIA; LIVER TOXICITY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PAIN; PRIORITY JOURNAL; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA;

EID: 53049087362     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn365     Document Type: Article

References (30)

1. Duggan DB, Petroni GR, Johnson JL el al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an Intergroup trial. J Clin Oncol 2003; 21: 607-614.
2. Diehl V, Franklin J, Pfreundschuh M et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386-2395.
3. Hinz M, Lemke P, Anagnostopoulos I et al. Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med 2002; 196: 605-617.
4. Hinz M, Loser P, Mathas S et al. Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Stemberg cells. Blood 2001; 97: 2798-2807.
5. Emmerich F, Meiser M, Hummel M et al. Overexpression of I kappa B alpha without inhibiton of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Stemberg cells. Blood 1999; 94: 3129-3134.
6. Mitsiades N, Mitsiades CS, Poulaki V et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002; 99: 14374-14379.
7. Ling YH, Liebes L, Jiang JD et al. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines, Clin Cancer Res 2003; 9: 1145-1154.
8. Pham LV, Tamayo AT, Yoshimura LC et al. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003; 171: 88-95.
9. Fisher RI, Bemstein SH, Kahl BS et al. Multicenter phase II study of botezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24: 4867-4874.
10. Mitchell BS. The proteasome - an emerging therapeutic target in cancer. N Engl J Med 2003; 348: 2597-2598.
11. Boll B, Hansen H, Heuck F et al. The fully human anti-CD30 antibody 5F11 activates NF-κB and sensitizes lymphoma cells to bortezomib-induced apoptosis. Blood 2005; 106: 1839-1842.
12. Noble S, Goa KL. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 1997; 54: 447-472.
13. Friedberg JW, Neuberg D, Kim H et al, Gemcitabine added to doxorubicin, bleomycin, and vinblastine (ABVG) for the treatment of de novo Hodgkin's disease (HD): Unacceptable acute pulmonary toxicity. Cancer 2003; 98: 978-982.
14. Lucas A Horwitz SM, Homing SJ et al. Gemcitabine is active in relapsed Hodgkin's disease. J Clin Oncol 1999; 17: 2627-2628.
15. Zinzani PL, Bendandi M, Stefoni V et al. Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. Haematologica 2000; 85: 926-929.
16. Santoro A, Bredenfeld H, Devizzi L et al. Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicenter phase II study. J Clin Oncol 2000; 18: 2615-2619.
17. Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 2001; 100: 11-17.
18. Fahy BN, Schlieman MG, Virudachalam S et al. Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer. J Surg Res 2003; 113: 88-95.
19. Chung V, Zhou B, Liu X et al. SUMOylation plays a role in gemcitabine- and bortezomib-induced cytatoxicity in human oropharyngeal carcinoma KB gemcitabine-resistant clone. Mol Cancer Ther 2006; 5: 533-540.
20. Kamat AM, Karashima T, Davis DW et al. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther 2004; 3: 279-290.
21. Mortenson MM, Schlieman MG, Virudachalam S et al. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Cancer Chemother Pharmacol 2004; 54: 343-353.
22. Denlinger CE, Rundall BK, Keller MD et al. Proteasome inhibition sensitize non-small-cell lung cancer to gemcitabine-induced apoptosis. Ann TDorac Surg 2004; 78: 1207-1214: discussion 1207-1214.
23. Ryan DP, Appleman LJ, Lynch T et al. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors. Cancer 2006; 107: 2482-2489.
24. Cheson 8D, Horning SJ, Goiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
25. Bartlett NL, Niedzwiecki D, Johnson JL et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007; 18: 1071-1079.
26. Strauss SJ, Maharaj L, Hoare S et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: Potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 2006; 24: 2105-2112.
27. Blum KA, Johnson JL, Niedzwiecki D et al. Single agent borlezomib in the treatment at relapsed and refractory Hodgkin lymphoma: Cancer and leukemia Group B protocol 50206. Leuk Lymphoma 2007; 48: 1313-1319.
28. Trelle S, Sezer O, Naumann R et al. Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: Results of a prematurely closed phase II study. Haematologica 2007; 92: 568-569.
29. Alberts SR, Foster NR, Morton RF et al. PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: A North Central Cancer Treatment Group (NCCTG) randomized phase II study. Ann Oncol 2005; 16: 1654-1661.
30. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology 2006; 43: S99-S112.